GE HealthCare Technologies Inc. 8-K

What Happened

• GE HealthCare Technologies Inc. filed an 8‑K reporting that on March 13, 2026 the Board appointed Kevin A. Lobo as a director, effective immediately, and named him to the Talent, Culture, and Compensation Committee. His term runs until the Company’s 2026 Annual Meeting of Stockholders.
• Also on March 13, 2026, directors Risa Lavizzo‑Mourey and Tomislav Mihaljevic informed the Board they will not stand for re‑election at the 2026 Annual Meeting due to other commitments; their decisions were not due to any disagreement with the company.

Key Details

• Appointment date: March 13, 2026; press release furnished March 17, 2026.
• Mr. Lobo will be paid under the company’s non‑employee director compensation program (as described in the April 10, 2025 proxy) and will enter into the company’s standard indemnification agreement.
• The filing states there is no arrangement or understanding related to Mr. Lobo’s selection and no reportable transactions between him and the company under Item 404(a).
• Both departing directors said their decisions were unrelated to company operations, policies, or practices.

Why It Matters

• Board changes affect corporate oversight and governance. Adding Kevin Lobo and his committee role may influence compensation and talent oversight, while the departures reduce board continuity until replacements are elected at the 2026 Annual Meeting.
• For shareholders, these are governance updates to monitor—particularly any future nominations or shifts in committee composition that could follow the announced changes.